logo
logo
Orthofix Medical Inc.

Orthofix Medical Inc.

NASDAQ•OFIX
CEO: Mr. Geoffrey C. Gillespie
セクター: Healthcare
業種: Medical - Devices
上場日: 1992-04-24
Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
連絡先情報
3451 Plano Parkway, Lewisville, TX, 75056, United States
214-937-2000
www.orthofix.com
時価総額
$534.60M
PER (TTM)
-4.5
29.9
配当利回り
--
52週高値
$20.48
52週安値
$10.24
52週レンジ
32%
順位38Top 36.9%
4.3
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 4.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$205.63M+4.59%
直近4四半期の推移

EPS

-$0.57-19.72%
直近4四半期の推移

フリーCF

$2.50M-57.37%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Reported Net Sales Growth Q3 reported net sales totaled $205.6M USD, reflecting 4.6% growth versus prior year period.
Gross Profit Increased 10% Quarterly gross profit reached $148.5M USD, marking a strong 10.0% increase compared to 2024.
EBITDA Margin Expansion Non-GAAP pro forma adjusted EBITDA was $24.6M USD, with margin expanding approximately 233 basis points.
Orthopedics Segment Sales Global Orthopedics segment sales reached $33.6M USD for the quarter, achieving 10.1% reported growth.

リスク要因

Executive Arbitration Accrual Recorded $18.3M accounting accrual reflecting estimated value of severance/equity rights related to executive arbitration.
M6 Product Line Impairment Recognized $32.2M loss on M6 inventories and long-lived assets impairment during the nine months ended September 30.
SG&A Expense Driven by Legal SG&A increased $18.0M for the quarter, driven primarily by $13.2M associated with ongoing legal matters costs.

見通し

Debt Covenant Compliance Maintained Confirmed compliance with all required debt-to-EBITDA leverage ratio covenants as of September 30, 2025.
Inventory Efficiency Improved Inventory turns improved to 1.5 times compared to 1.2 times reported in the prior year period.
New Tax Disclosure Adopted Adopted ASU 2023-09 standard for income tax disclosures, effective prospectively starting January 1, 2025.

同業比較

売上高 (TTM)

Varex Imaging CorporationVREX
$854.40M
+4.1%
Orthofix Medical Inc.OFIX
$818.06M
+4.3%
Avanos Medical, Inc.AVNS
$699.90M
+2.7%

粗利益率 (最新四半期)

Absci CorporationABSI
100.0%
+197.2pp
KalVista Pharmaceuticals, Inc.KALV
91.0%
+0.0pp
SI-BONE, Inc.SIBN
79.8%
+0.8pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
MLTX$1.24B-5.3-56.2%18.3%
SVRA$1.17B-10.7-86.6%21.2%
BFLY$767.91M-9.6-37.8%7.3%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-1.6%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年2月24日
|
EPS:$0.44
|
売上高:$218.71M
財務レポート
財務データ
ニュース
全年度
  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月4日|
    売上高: $205.63M+4.6%
    |
    EPS: $-0.57-19.7%
    予想を上回る
  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月5日|
    売上高: $203.12M+2.3%
    |
    EPS: $-0.36-59.1%
    予想を上回る
  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月6日|
    売上高: $193.65M+2.7%
    |
    EPS: $-1.35+42.1%
    予想を下回る
  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月25日|
    売上高: $799.49M+7.1%
    |
    EPS: $-3.30+19.9%
    予想を下回る
  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月7日|
    売上高: $196.61M+6.8%
    |
    EPS: $-0.71-7.8%
    予想を下回る
  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月6日|
    売上高: $198.62M+6.2%
    |
    EPS: $-0.88-17.8%
    予想を下回る
  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月7日|
    売上高: $188.61M+7.7%
    |
    EPS: $-0.95-44.4%
    予想を下回る
  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月5日|
    売上高: $746.64M+62.1%
    |
    EPS: $-4.12-320.4%
    予想を下回る